0001144204-14-011475.txt : 20140225 0001144204-14-011475.hdr.sgml : 20140225 20140225170130 ACCESSION NUMBER: 0001144204-14-011475 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20140225 DATE AS OF CHANGE: 20140225 EFFECTIVENESS DATE: 20140225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INNOVUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001411879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870324697 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-212502 FILM NUMBER: 14641514 BUSINESS ADDRESS: STREET 1: 4275 EXECUTIVE SQUARE, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-964-5123 MAIL ADDRESS: STREET 1: 4275 EXECUTIVE SQUARE, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: North Horizon, Inc. DATE OF NAME CHANGE: 20070910 D 1 primary_doc.xml X0707 D LIVE 0001411879 INNOVUS PHARMACEUTICALS, INC. 9171 TOWNE CENTRE DRIVE, SUITE 440 SAN DIEGO CA CALIFORNIA 92122 858-964-5123 NEVADA None North Horizon, Inc. Corporation true Bassam Damaj 9171 Towne Centre Drive, Suite 440 San Diego CA CALIFORNIA 92122 Executive Officer Director Vivian Liu 9171 Towne Centre Drive, Suite 440 San Diego CA CALIFORNIA 92122 Director Henry Esber 9171 Towne Centre Drive, Suite 440 San Diego CA CALIFORNIA 92122 Director Pharmaceuticals Decline to Disclose 06b false 2014-02-19 false true false 0 742300 742300 0 Conversion of $742,300 worth of prinicpal and interest under the Company's 8% Debentures into 1,855,745 shares of the Company's common stock at a conversion rate of $0.40 per share false 6 0 0 0 false INNOVUS PHARMACEUTICALS, INC. /s/ Lynnette Dillen Lynnette Dillen Executive Vice President, Chief Financial Officer 2014-02-25